Press Release

Welcome Carlos A. Urrea MD, MPH to the Board of Directors

picture of Carlos A. Urrea

January 15, 2024 – Kreg Therapeutics, a manufacturer and service provider of innovative ICU hospital beds, is pleased to announce the appointment of Carlos A. Urrea MD, MPH to its Board of Directors. In this role, Dr. Urrea will play a key part in guiding the strategic direction and growth of the company.

Dr. Urrea brings a wealth of clinical and regulatory experience and expertise to his board position. Dr. Urrea is a clinical global leader in Medical Affairs within the medical device industry who brings a global perspective in product development, evidence generation, and management of regulatory matters. He received his medical degree from the National University of Colombia in 2001 and holds a Master of Public Health from Johns Hopkins Bloomberg School of Public, and a Master of Science in Health Services Administration from Barry University.

Most recently, Dr. Urrea served as Vice President, Medical Affairs, at Hillrom/Baxter providing medical oversight for evidence generation and dissemination activities and offered guidance in product development, pipeline, and digital health strategy. Today, Dr. Urrea is the co-founder of PLU Ophthalmic, a medical device company helping ophthalmologists improve the surgical treatment of Glaucoma.

“We are thrilled to welcome Carlos to our Board of Directors,” said Christian Jorgensen, CEO. “Carlos’s dedication to improving patient outcomes, especially in mobilization and ICU care, is truly inspiring. Having successfully led clinical efforts at Hillrom/Baxter, he brings a wealth of expertise and a track record of excellence. His immediate recognition of Verticalization Therapy as a game-changer for every ICU nationwide fueled our joint commitment to work together to accelerate care for complex patients.”

Carlos A. Urrea MD, MPH expressed excitement about joining Kreg and shared his thoughts on the appointment. “I am honored to be part of such an innovative and forward-thinking company,” said Dr. Urrea. ” Our collective objective is clear; to empower clinicians to transition complex patients quickly, and safely, out of the ICU and back into their homes with improved outcomes while reducing the overall cost of care.”

About Kreg Therapeutics:

Kreg Therapeutics is a Chicago-based specialty bed company focused on improving patient outcomes and reducing length of stay for the most complex patients. Kreg designs and manufactures their beds in the USA, and their Kreg Service Centers can be found less than three hours from their customers.